@phdthesis{
author = "Rakić, Mia",
year = "2012",
abstract = "Uvod. Peri-implantitis predstavlja inflamatorni proces koji se karakteriše gubitkom potporne
kosti opterećenog oralnog implantata. Osnovna patološka karakteristika peri-implantitisa je
gubitak potporne kosti implantata u funkciji. Ovaj proces je zasnovan na inflamatornoj
osteoklastogenezi koja ujedno predstavlja centralni patološki proces peri-implantitisa.
Inflamatorna osteoklastogeneza predstavlja proces sazrevanja pre-osteoklasta i pojačavanje
aktivnosti zrelih osteoklasta pod uticajem kritičnih koncentracija pro-inflamatornih
medijatora. Kliničke karakteristike peri-implantitisa nisu strogo definisane i variraju iz
prostog razloga jer dubina peri-implantnog sulkusa značajno varira s'toga dubina džepa
predstavlja individualnu determinantu. Istovremeno, proces gubitka marginalne kosti
predstavlja fiziološku pojavu koja je najintezivnija u prvoj godini opterećenja, i istraživanja su
pokazala da iznosi -0.78mm mezijalno i -0.85mm distalno, a zatim se kontinurano odvija i na
godišnjem nivou iznosi oko 0.2mm. Pomenuta vrednost iznosi prosečnu vrednost ali ona
takođe individualno varira i uslovljena je tipom implantata, dizajnom abatmenta i mnogim
drugim faktorima. Iz tog razloga se relativni nivo pripojnog epitela (rCAL) kao ni radiološki
evidentan gubitak kosti ne mogu usvojiti kao apsolutni indikatori patološkog gubitka kosti. U
dijagnostici stanja peri-implantnih tkiva koristi se nekoliko tipova metoda i najčešće u
kombinaciji radi što potpunijeg postavljanja dijagnoze. Dijagnostičke metode uključuju:
određivanje kliničkih parametara, radiološke analize, mikrobiološke analize i kvalitativne i
kvantitativne analize peri-implantnte krevikularne tečnosti (PICF). Analiza PICF predstavlja
jednu od najatraktivnijih metoda u savremenoj implantologiji, pri čemu je njena najveća
vrednost u tome što daje direktne informacije o stanju peri-implantinh tkiva i zasnovano na
tome poseduje mogućnost da pokaže rane znake oboljenja peri-implantnih tkiva u fazi gde su
tkivne promene reverzibilne. Ovo ograničenje kliničkih metoda rezultira u propuštanju
vremena od momenta pojave bolesti koje proporcijonalno umanjuje uspeh terapije, a često i u
izboru neadekvatnog terapijskog plana. Zasnovano na tome, metoda merenja specifičnih
biomarkera u uzorku PICF nadomešćuje ograničenja konvencionalnih kliničkih dijagnostičkih
metoda koje daju informacije u stadijumu razvijene bolesti. Brojne studije se sprovode u cilju
identifikacije biomolekula koji pouzdano reflektuje stanje peri-implantnih tkiva, ali kako je
patologija lokalnog meatbolizma kompleksna, a metoda evaluacije visoko-osetljiva,
standardizacija ove metode je još uvek u toku. Cilj istraživanja bio je da se ispIta potencijal
RANK-a, sRANKL-a, OPG-a, Katepsina-K, Sklerostina i VEGF-a kao biomarkera gubitka
potporne kosti implantata. Materijal i metode. Studija je obuhvatila tri grupe sistemski
zdravih nepušača sa ugrađenim endoesealnim oralnim implantatima, opterećenih tokom
najmanje godinu dana (35 sa peri-implantitisom, 30 sa peri-mukozitisom i 30 sa zdravim periimplantnim
tkivima). Kriterijum isključenja su bili: upotreba antibiotika u predhodna tri
meseca i upotreba antiinflamatorika u predhodna dva meseca od trenutka uzorkovanja,
menstrualni ciklus, trudnoća i laktacija, pušenje i tretiranost parodontalnih/peri-implantnih
tkiva u poslednjih godinu dana. Klinička merenja su obavljena u 6 tačaka (buko-mezijalna,
buko-medijalna, buko-distalna, oro-distalna, oro-medijalna i oro-mezijalna) i uključiće
određivanje: krvarenja na probu (BOP) odsustvo-0, prisustvo-1, 15 sekundi nakon sondiranja,
indeks akumulacije plaka (PI) odsustvo-0, prisustvo-1 duž marginalne ivice, PD i rNPE
graduisanom sondom (North Carolina–Hu-Friedy, Chicago, IL, USA). U slučaju prisustva
više peri-implantitisa ili peri-mukozitisa kod jednog pacijenta, zapaljenje sa većim defektom
je bilo uključeno u studiju, a u slučaju sličnih karakteristika defekta u 6 tačaka, najdostupnije,
odnosno anterijorno mesto je birano kao reprezentativno. Uzorak peri-implantne tečnosti
sakupljan je sa mezijalne površine reprezentativnog implantata participanta studije. Uzorci su
uzimani 24 časa nakon kliničkih merenja kako bi se izbegla kontaminacija uzorka krvlju, u
grupama sa zapaljenjem sa mesta sa najvećom dubinom sondiranja, a u grupi zdravih periimplantnih
tkiva sa najdostupnijeg mesta. Uzorci PCF su uzimani sa reprezentativnog mesta
metodom filter papira, a dobijeni volumen tečnosti iz tračica je određivan pomoću
kalibrisanog aparata Periotron 6000 (Interstate Drug Exchange, Amityville, NY, USA).
Komercijalni "enzyme-linked immunosorbent assay" (ELISA) kitovi su korišćeni za
evaluaciju koštanih biomarkera u uzorku PICF: Human RANK/TNFRSF11A (DuoSet, R&D
Systems Inc., Minneapolis, MN, USA), ampli-sRANKL, OPG, cathepsin-K i sclerostin
(Biomedica Gruppe, Vienna, Austria) i VEGF (Human VEGF ELISA Development Kit,
Promokine, PromoCell GmbH, Heidelberg, Germany). Rezultati. U svim analiziranim
uzorcima PICF-a su dokazane koncentracije RANK-a, sRANKL-a, OPG-a, katepsina-K i
VEGF-a iznad detekcionog limita, pri čemu je za sklerostin samo 6% uzoraka bilo pozitivno.
Koncentracija RANK-a je bila značajno veća kod peri-implantitisa u odnosu na zdrava periimplantna
tkiva (p=0.002), takođe je bila veća i kod peri-mukozitisa u odnosu na zdrave
implantate (p=0.021). Vrednosti sRANKL-a bile su značajno veće u grupi peri-implantitisa u
odnosu na zdrava peri-implantna tkiva (p=0.010), ali ne i u odnosu na peri-mukozitise, kao ni
između peri-mukozitisa i zdravih peri-implantnih tkiva, gde nije postignuta statistička
značajnost. Koncentracija OPG-a je bila značajno veća kod peri-implantitisa u odnosu na
zdrava peri-implantna tkiva (p=0.031), i to je ujedno bila jedina značajnost za ovaj marker.
Vrednosti katepsina-K su bile više na mestima zapaljenja, ali je jedina značajnost uočena
između peri-mukozitisa i zdravih peri-implantnih tkiva (p=0.039). Sklerostin je dokazan u
izuzetno malom broju uzoraka, ali su razlike bile upadljive pa su vrednosti bile značajno veće
u grupi peri-implantitisa u odnosu na druge dve grupe. Koncentracija VEGF-a je bila
značajno veća kod peri-implantitisa u odnosu na druge dve grupe, i grupu peri-mukozitisa
(p=0.014) i zdravih peri-implantnih tkiva (p=0.000). RANK i sRANKL su pokazali značajno
pozitivnu korelaciju sa svim merenim kliničkim parametrima, a OPG je pokazao takođe
značajnu pozitivnu korelaciju sa gotovo svim merenim kliničkim parametrima, izuzev sa PI
(p=0.121), a identičan slučaj je bio sa sklerostinom. VEGF nije pokazao nijednu značajnu
korelaciju sa merenim kliničkim parametrima. Zaključak. RANK, sRANKL, OPG, skelrostin i
VEGF su biomarkeri koji su udruženi sa peri-implantitisom. Katepsin-K predstavlja
biomarker svosjtven peri-mukozitisu. Evaluirani biomarkeri su drugačije distribuirani u
različitim regionima vilica i u PICF implantata različitih dijametara. RANK i OPG su
značajno povišeni u frontalnom regionu maksile, što ujedno ukazuje na intezivnije
osteolitičke procese u ovom regionu. RANK i katepsin-K su značajno povišeni u grupi
implantata sa najvećim dijametrom, što na molekularnom nivou potvrđuje predhodne
rezultate kliničkih studija da su dijametar implantata i gubitak implantata u pozitivnoj
korelaciji., Introduction. Peri-implantitis is inflammatory process characterized by supporting bone loss
of loaded oral implants. The pathognomonic characteristic of peri-implantitis is supporting
bone loss of the loaded implant. This process is based on inflammatory osteoclastogenesis
which simultaneously represent the central pathologic process of the disorder. Inflammatory
osteoclastogenesis implies maturation of pre-osteoclasts and enhancement of the activity of
maturated osteoclasts which are induced by achieving of the critical concentrations of proinflammatory
mediators. Clinical characteristics of the peri-implantitis are still not strictly
defined and they vary because in the physiological conditions the values of clinical
parameters varies among individuals, for example peri-implant sulcus depth represents the
individual determinant which could be from 0.5mm to 4mm as well. Simultaneously, the
marginal bone loss is the physiological characteristic around implants in function, which is
the most intensive in the first year of loading represented by the -0.78mm in the mesial sites
and -0.85mm at the distal sites, and after that the process is constant and bone loss at the year
level is approximately 0.2mm. The mentioned value is the average values that individually
vary and it depends of the implant type, abutments and numerous other factors. From that
reason the relative clinical attachment level (rCAL), nether radiological proof of bone loss
could be accepted as the absolute indicators of the pathological bone loss. In the peri-implant
diagnostics the most frequently are used the few different diagnostic procedures in the
combination to give the complete diagnostic view. These diagnostic methods include:
evaluation of clinical parameters, radiological analyses, microbiological analyses and
quantitative and qualitative analyses of PICF. The PICF analysis is one of the most attractive
methods in current implantology, where the one of the most precious values is providing of
the direct information on peri-implant tissues d based on that providing information on early
disease onset in the phase of reversible damage. This limitation of clinical methods results in
time loss proportionally decreasing treatment success, and frequently resulting in
inappropriate treatment planning. Based on that, evaluation of biomarkers in PICF sample
compensates limitations of conventional diagnostic procedures without capability to provide
accurate information on early disease. Numerous studies have been conducted to identify the
biomolecules accurately reflecting peri-implant tissue condition, but since the pathology of
local metabolism is complex, the method for evaluation is still under standardization.
Objective. The objective of the study was to investigate potential of RANK, sRANKL, OPG,
Cathepsin-K, Sclerostin and VEGF as biomarkers of implant supporting bone loss. Material
and methods. Study included three groups of systemically healthy non smokers with
osseointegrated endosseal implants loaded for at least one year (35 with peri-implantitis, 30
with peri-mucositis and 30 with healthy peri-implant tissues). Exclusion criteria were the
following: antibiotics usage in the preceding three months and anti-inflammatorics in
preceding two months from the moment of sampling, menstruation, pregnancy and lactation,
smoking and periodontal/peri-implant treatment during last year. The following clinical
measurements have been performed in 6 points (bucco-mesial, bucco -medial, bucco -distal,
oro-distal, oro-medial and oro-mesial): Bleeding on Probing (BOP) measured 15 seconds after
probing and recorded as presence (1) or absence (0), Visible plaque accumulation (PI)
measured along the mucosal margin and recorded as presence (1) or absence (0), Probing
Pocket Depths (PPD) in mm and Relative Clinical Attachment Level (rCAL) (expressed in
mm) using a periodontal probe graded in mm (North Carolina–Hu-Friedy, Chicago, IL, USA).
In the case of few similar pathological processes in the same patient, the site representing the
greatest defect was sampled, and in the case of defects showing similar clinical
characteristics, the most accessible was included. PICF samples were collected from the
mesial aspects of one representative implant site in each individual participating in the study.
The specimens were retrieved 24 h after the clinical examination to avoid any contamination
with blood, from both peri-implant and periodontal sites, selected from those demonstrating
the deepest probing depth. The samples were retrieved using the filter paper technique, and
obtained volume was evaluated using calibrated Periotron 6000 (Interstate Drug Exchange,
Amityville, NY, USA). Commercial enzyme linked immunosorbent kits (ELISA) were used
for evaluation of biomarkers in PICF samples: Human RANK/TNFRSF11A (DuoSet, R&D
Systems Inc., Minneapolis, MN, USA), ampli-sRANKL, OPG, cathepsin-K i sclerostin
(Biomedica Gruppe, Vienna, Austria) i VEGF (Human VEGF ELISA Development Kit,
Promokine, PromoCell GmbH, Heidelberg, Germany). Results. In all tested PICF samples
were detected RANK, sRANKL, OPG, cathepsin-K and VEGF, indicating the concentrations
above detection limit, but only 6% of the samples were positive on sclerostin. RANK
concentration was significantly higher in peri-implantitis when compared to healthy periimplant
tissues (p=0.002), and it was higher when compared to peri-mucositis as well
(p=0.021). sRANKL values were significantly higher in peri-implantitis when compared to
healthy peri-implant tissues (p=0.010), but not when compared to peri-mucositis, nether perimucositis
an healthy peri-implant tissues. OPG concentration was significantly higher in periimplantitis
when compared to healthy peri-implant tissues (p=0.031), and that was single
significance obtained for this marker. sRANKL/OPG relative ration did not show significant
difference in distribution between investigated groups. Cathepsin-K were in general higher in
inflammed sites, but the single significance was reached among peri-mucositis and healthy
peri-implant tissues (p=0.039). Sclerostin was detected in small sample size, but the
differences were clearly higher in peri-implantitis group when compared to both two groups.
VEGF concentration was significantly higher in peri-implantitis when compared to healthy
peri-implant tissues (p=0.000) and peri-mucositis as well (p=0.014). RANK and sRANKL
showed significantly positive correlation with all measured clinical parameters, and OPG
showed significantly positive correlation with all measured clinical parameters as well, with
exception of PI (p=0.121), and an identical case was with sclerostin. VEGF showed no
significant correlations with clinical parameters. Conclusion. RANK, sRANKL, OPG,
sclerostin and VEGF are biomarkers related to peri-implantitis. Cathepsin-K was the marker
related to peri-mucositis. Evaluated in this study are differently distributed in different jaws
regions and in PICF samples of implants with different diameter. RANK and OPG were
significantly elevated in frontal maxillary region, indicating more intensive osteolytic
processes in this region. RANK and cathepsin-K were significantly increased in the group o
implants with highest diameter, which supports on molecular level the previous results of
clinical studies that showed positive correlation between implant diameter and implant loss.",
publisher = "Belgrade: University of Belgrade, Faculty of Dental Medicine",
journal = "University of Belgrade, Faculty of Dental Medicine",
title = "Određivanje biomarkera gubitka alveolarne kosti kod pacijenata sa peri-implantitisom, Determination of alveolar bone loss biomarkers related to peri-implantitis",
pages = "1-70",
url = "https://hdl.handle.net/21.15107/rcub_nardus_2684"
}